Sino Biological, Inc., a global biotechnology company specializing in recombinant proteins, antibodies, and CRO services, has announced the launch of two dedicated target protein collections aimed at supporting AI-driven discovery. The collections, AI-Trusted Proteins and AI-Qualified Proteins, provide researchers with access to proteins that have demonstrated utility in AI research, experimentally characterized binding activity, and specialized formats for diverse AI-driven validation.
The announcement comes as artificial intelligence accelerates recombinant protein and antibody discovery for therapeutic and diagnostic development. Access to well-characterized target proteins is essential for evaluating AI-designed molecules, and the new collections aim to fill that need. The AI-Trusted Proteins collection includes over 600 targets and 960 individual proteins, with characterization data that may include SPR, BLI, ELISA, cell-based activity assays, SEC-HPLC, and SEC-MALS analyses. These proteins have been used in AI-focused company validation projects, and some are featured in published research. The AI-Qualified Proteins collection offers 680 targets and 1,700 individual proteins, featuring experimentally characterized target binding activity, including SPR/BLI validation data, as well as specialized formats such as biotinylated proteins.
Supporting these collections is Sino Biological's 4S System, which stands for Scale, Scope, Speed, and Supply. The system provides access to more than 11,000 recombinant target proteins, including over 1,200 biotinylated proteins, broad coverage of membrane, extracellular, and intracellular proteins, rapid production and delivery, and lot-to-lot consistency with reliable long-term supply. The company has also developed a therapeutic target directory covering 12 therapeutic areas and more than 100 diseases.
The new collections are part of Sino Biological's 4RISE AI Lab Validation Solution, which integrates high-throughput protein expression, binding and affinity characterization, developability assessment, and functional validation. "AI-driven discovery depends on reliable experimental resources to evaluate designed molecules and guide subsequent research decisions," said Dr. Rob Burgess, Chief Business Officer at Sino Biological US. "By combining AI-Trusted and AI-Qualified target proteins with our 4S System, we aim to provide researchers with well-characterized target resources, broad coverage, and dependable supply to support AI-driven protein and antibody discovery."
For the biotechnology industry, the launch addresses a growing challenge: as AI models generate increasing numbers of candidate molecules, the need for high-quality experimental validation resources becomes more acute. By offering well-characterized proteins with documented binding data and specialized formats, Sino Biological aims to help researchers bridge the gap between computational predictions and experimental evidence. The company serves researchers in more than 90 countries, supporting basic research, drug discovery, vaccine development, and diagnostics. The original release can be viewed on www.newmediawire.com, and more information about the company is available at www.sinobiological.com.


